Results of nonmyeloablative SCT in lymphoproliferative disease
| Author . | NHL . | FL . | Conditioning . | Graft rejection . | Mixed chimerism . | TRM . | aGVHD . | DFS . | OS . |
|---|---|---|---|---|---|---|---|---|---|
| Nagler et al197 | 19 of 4 HD | NA | Fludarabine-busulfan-ATG CyA | 0 | 30% | 30% | Gr 2-4, 34% Gr 3-4, 17% cGVHD, 17% | 40% (37 mo) | 40% |
| Dreger et al198 | 7 | 1 | Fludarabine-CY CyA-Methotrexate | 0 | 42% then 0% | 28% | Gr 3-4, 28% cGVHD, 3 of 5 | 71% (14 mo) | 71% |
| Sykes et al199 (103 d) | 5 | 0 | CY thymic irradiation ATG CyA Haploidentical related donor | 0 | 4/5 | 2/5 | Gr 2-4, 5 of 5 Gr 3-4, 3 of 5 | 1CR (460 d) 1 PR | 2 of 5 |
| Khouri et al161 | 9 CLL | 6 | 11 Fludarabine-CY 4 Fludarabine AraC cisplatine CyA-tacrolimus | 26% (3/4 low-dose Fludarabine) | 63% | 40% | Gr 2-4, 26% Gr 3-4, 6% cGVHD, 13% | 33% (1 y) | 50% |
| Khouri et al187 | 20 | 18 | Fludarabine-CY ± rituximab (9) CyA-tacrolimus | 0 | 5% | 10% | Gr 2-4, 20% Gr 3-4, 5% cGVHD, 64% | 84% (21 mo) | 84% |
| Mohty et al195 (108 d, 326 d) | 11 | 3 NHL | Fludarabine-busulfan ± ATG (3) CyA steroids | 0 | 45% | 36% | Gr 2-4, 54% Gr 3-4, 54% | 9% (326 d) | 27% (108 d, 326 d, 536 d) |
| Hou et al200 (100 d) | 14 | 4 | Fludarabine-CY (after 3 EPOCH-fludarabine) CyA | 0 | 0% | 7% | Gr 2-4, 71% | 69% (100 d) | 76% (100 d) |
| Carella et al196 | 15 | 5 NHL | CY + G-CSF, leukapheresis 0 Beam + ASCT Fludarabine-CY CyA methotrexate DLI 7 patients | 0 | 17% | 6% | Gr 2-4, 46% Gr 3-4, 15% cGVHD, 15% | 33% | 66% |
| Author . | NHL . | FL . | Conditioning . | Graft rejection . | Mixed chimerism . | TRM . | aGVHD . | DFS . | OS . |
|---|---|---|---|---|---|---|---|---|---|
| Nagler et al197 | 19 of 4 HD | NA | Fludarabine-busulfan-ATG CyA | 0 | 30% | 30% | Gr 2-4, 34% Gr 3-4, 17% cGVHD, 17% | 40% (37 mo) | 40% |
| Dreger et al198 | 7 | 1 | Fludarabine-CY CyA-Methotrexate | 0 | 42% then 0% | 28% | Gr 3-4, 28% cGVHD, 3 of 5 | 71% (14 mo) | 71% |
| Sykes et al199 (103 d) | 5 | 0 | CY thymic irradiation ATG CyA Haploidentical related donor | 0 | 4/5 | 2/5 | Gr 2-4, 5 of 5 Gr 3-4, 3 of 5 | 1CR (460 d) 1 PR | 2 of 5 |
| Khouri et al161 | 9 CLL | 6 | 11 Fludarabine-CY 4 Fludarabine AraC cisplatine CyA-tacrolimus | 26% (3/4 low-dose Fludarabine) | 63% | 40% | Gr 2-4, 26% Gr 3-4, 6% cGVHD, 13% | 33% (1 y) | 50% |
| Khouri et al187 | 20 | 18 | Fludarabine-CY ± rituximab (9) CyA-tacrolimus | 0 | 5% | 10% | Gr 2-4, 20% Gr 3-4, 5% cGVHD, 64% | 84% (21 mo) | 84% |
| Mohty et al195 (108 d, 326 d) | 11 | 3 NHL | Fludarabine-busulfan ± ATG (3) CyA steroids | 0 | 45% | 36% | Gr 2-4, 54% Gr 3-4, 54% | 9% (326 d) | 27% (108 d, 326 d, 536 d) |
| Hou et al200 (100 d) | 14 | 4 | Fludarabine-CY (after 3 EPOCH-fludarabine) CyA | 0 | 0% | 7% | Gr 2-4, 71% | 69% (100 d) | 76% (100 d) |
| Carella et al196 | 15 | 5 NHL | CY + G-CSF, leukapheresis 0 Beam + ASCT Fludarabine-CY CyA methotrexate DLI 7 patients | 0 | 17% | 6% | Gr 2-4, 46% Gr 3-4, 15% cGVHD, 15% | 33% | 66% |
TRM indicates transplantation-related mortality; aGVHD, acute graft versus host disease; PR, partial remission; DFS, disease-free survival; PFS, progression-free survival; OS, overall survival; CyA, cyclosporine A; ATG, anti-thymoglobulin; and CY, cyclophosphamide.